1. KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer. (2nd December 2019) Authors: Ergun, Yakup; Acikgoz, Yusuf; Bal, Oznur; Ucar, Gokhan; Dirikoc, Merve; Caliskan Yildirim, Eda; Akdeniz, Nadiye; Uncu, Dogan Journal: Expert review of molecular diagnostics Issue: Volume 19:Number 12(2019) Page Start: 1131 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗